-
Drug Ming Juno, a leader in cell immunotherapy, is listed on the main board of the Hong Kong Stock Exchange
Time of Update: 2021-03-07
The company has established an integrated platform dedicated to the development, manufacture and commercialization of breakthrough cell immunotherapy for blood and solid tumors.
-
Seven years after the U.S. stock market was de-listed, Synth Pharmaceuticals listed on the Hong Kong Stock Exchange
Time of Update: 2021-03-07
Although the core revenue of Synth Pharmaceuticals still relies on traditional products, nearly 50 new drugs in the future will inevitably bring new changes to China's pharmaceutical industry.
-
Beida Pharmaceuticals is going to the Hong Kong Stock Exchange to list, and two more anti-cancer
Time of Update: 2021-03-04
cancer, ensartinib, in the second decade. this is a new powerful, highly selective new generation of APK inhibitors, by effectively inhibiting the activity of APK, to inhibit tumor growth. 2020, Nsatinib was approved for listing in China
-
"Stock speculation" loss of 1.378 billion yuan Shanghai Lais "Blood King" status is difficult to protect
Time of Update: 2021-02-28
On February 22 this year, Shanghai Laix suspended trading on the grounds of restructuring, with a market capitalisation of 97.1 billion yuan, still ranking fourth in the A-share pharmaceutical industry.
-
In the first half of the year, the fund's top 30 stocks were 90% heavy-stock pharmaceutical stocks
Time of Update: 2021-02-28
States" market, for the public fund to contribute a lot of income. The performance of the two fund managers was eye-catching in the first half of this year, the market as a whole fell, with only leisure services, pharmaceuticals
-
More than 9 months after breaking up with Pfizer, Haizheng Pharmaceuticals has re-emerged out of stock
Time of Update: 2021-02-27
Haizheng Pharmaceuticals reproduces the phenomenon of out-of-stock. An exclusive letter to experts from a reporter for Securities Daily, a communication note on the temporary tight supply of Rui Yining (hereinafter referred
-
Affected by Hurricane Maria, Haizheng Pharmaceuticals is back out of stock
Time of Update: 2021-02-27
On September 3rd, Haizheng Pharmaceuticals issued an announcement on the supply of products (Rui Yining) from its controlling subsidiary, Hanyu Pharmaceutical Co., Ltd., and in late May 2018, Hanyu Pharmaceuticals received a notification from Pfizer
-
Take stock | more than 20 new Chinese drugs that will be eligible for FDA orphan drugs by 2020
Time of Update: 2021-02-24
According to incomplete statistics, more than 20 innovative products from Chinese biopharmaceutical companies will be eligible for orphan drugs by the FDA in 2020. these products, there are PD-1/L1 inhibitors, CAR-T therapy, antibody
-
Kang Caixin | shares on the Shanghai Stock Exchange Nelo listed coffee chewing beans
Time of Update: 2021-02-24
